DACLIZUMAB

Daclatasvir is an antiviral inhibiting HCV NS5A protein, used in hepatitis C therapy. Side effects include fatigue, headache, and nausea. Only GMP materials will be supplied, logistics all according to GDP.

SKU: d6482c30c064 Category: Tag:

Product Description


Mechanism of Action

Daclizumab is a humanized monoclonal antibody directed against the IL2 receptor alpha chain (CD25). By blocking IL2 binding, it inhibits highaffinity IL2 receptor signalling on activated Tcells, reducing clonal expansion and inflammatory responses. It also modulates innate lymphoid populations such as CD56bright NK cells.

Benefits and Advantages

Used in transplant immunology research, Tcell activation pathway studies, cytokinesignalling modelling, autoimmunedisease investigations and monoclonalantibody SAR analysis.

Side Effects and Risks

Risks include serious immunemediated encephalitis, hepatotoxicity, infections, hypersensitivity and autoimmune reactions. Handle with biologicagent containment and immunomodulator precautions.

Only GMP materials will be supplied, logistics all according to GDP.

Datasheet


Molecular Formula

C6450H9988N1720O2020S42

Molecular Weight

144000.0 g/mol

CAS Number

152923-56-3

Storage Condition

Store in a cool, dry place; protect from light

Solubility

Soluble in water

Purity

Purity information is available upon request (COA).

Synonym

Daclizumab; CLA1061; 152923-56-3

IUPAC/Chemical Name

Humanized monoclonal antibody

InChl Key

Unavailable

InChl Code

Unavailable

References

PubChem; ChemBL; FDA;

3D Conformer.

(Click, turn or enlarge)

Download our GMP API Product List.

MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.

Download